
The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.
Marcia S. Brose, MD, PhD, Abramson Cancer Center, University of Pennsylvania, discusses BRAF mutations in thyroid cancer.a
Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discussesBRAFmutations in thyroid cancer.






